Serum prolactin revisited:parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia by Overgaard, Martin & Pedersen, Susanne Møller
Syddansk Universitet
Serum prolactin revisited
parametric reference intervals and cross platform evaluation of polyethylene glycol
precipitation-based methods for discrimination between hyperprolactinemia and
macroprolactinemia
Overgaard, Martin; Pedersen, Susanne Møller
Published in:
Clinical Chemistry and Laboratory Medicine
DOI:
10.1515/cclm-2016-0902
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Citation for pulished version (APA):
Overgaard, M., & Pedersen, S. M. (2017). Serum prolactin revisited: parametric reference intervals and cross
platform evaluation of polyethylene glycol precipitation-based methods for discrimination between
hyperprolactinemia and macroprolactinemia. Clinical Chemistry and Laboratory Medicine, 55(11), 1744-1753.
DOI: 10.1515/cclm-2016-0902
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Clin Chem Lab Med 2017; 55(11): 1744–1753
Martin Overgaard* and Susanne Møller Pedersen
Serum prolactin revisited: parametric reference 
intervals and cross platform evaluation of 
polyethylene glycol precipitation-based methods 
for discrimination between hyperprolactinemia 
and macroprolactinemia
DOI 10.1515/cclm-2016-0902
Received October 7, 2016; accepted January 23, 2017; previously 
 published online February 25, 2017
Abstract
Background: Hyperprolactinemia diagnosis and treat-
ment is often compromised by the presence of biologically 
inactive and clinically irrelevant higher-molecular-weight 
complexes of prolactin, macroprolactin. The objective of 
this study was to evaluate the performance of two macro-
prolactin screening regimes across commonly used auto-
mated immunoassay platforms.
Methods: Parametric total and monomeric gender-specific 
reference intervals were determined for six immunoassay 
methods using female (n = 96) and male sera (n = 127) from 
healthy donors. The reference intervals were validated using 
27 hyperprolactinemic and macroprolactinemic sera, whose 
presence of monomeric and macroforms of prolactin were 
determined using gel filtration chromatography (GFC).
Results: Normative data for six prolactin assays included 
the range of values (2.5th–97.5th percentiles). Validation 
sera (hyperprolactinemic and macroprolactinemic; n = 27) 
showed higher discordant classification [mean = 2.8; 95% 
confidence interval (CI) 1.2–4.4] for the monomer reference 
interval method compared to the post-polyethylene glycol 
(PEG) recovery cutoff method (mean = 1.8; 95% CI 0.8–
2.8). The two monomer/macroprolactin discrimination 
methods did not differ significantly (p = 0.089). Among 
macroprolactinemic sera evaluated by both discrimina-
tion methods, the Cobas and Architect/Kryptor prolactin 
assays showed the lowest and the highest number of mis-
classifications, respectively.
Conclusions: Current automated immunoassays for pro-
lactin testing require macroprolactin screening methods 
based on PEG precipitation in order to discriminate truly 
from falsely elevated serum prolactin. While the recovery 
cutoff and monomeric reference interval macroprolactin 
screening methods demonstrate similar discriminative 
ability, the latter method also provides the clinician with 
an easy interpretable monomeric prolactin concentration 
along with a monomeric reference interval.
Keywords: assay interference; hyperprolactinemia; immu-
noassay; macroprolactinemia; polyethylene glycol precip-
itation; reference interval.
Introduction
Prolactin is a glycoprotein hormone secreted from the 
adenohypophysis whose principal function is exerted in 
the mammary glands by stimulating and sustaining lacta-
tion postpartum, as reviewed by Bernard et al. [1]. Elevated 
blood levels of prolactin (hyperprolactinemia) may have 
multiple causes including disorders of the hypothalamic-
pituitary axis such as prolactin-secreting pituitary adeno-
mas. Also, other conditions such as chronic renal failure, 
pregnancy, polycystic ovarian syndrome and primary 
hypothyroidism may cause hyperprolactinemia [2]. Medi-
cation such as dopamine antagonists may also lead to 
elevated prolactin because secretion in the pituitary is 
normally suppressed by dopamine. Symptoms related to 
hypersecretion of prolactin are gender specific and include 
galactorrhea, hypogonadism, infertility, and neurological 
symptoms such as visual field defects and headache.
Circulating prolactin predominantly exists as a bioactive 
monomer of 23 kDa that is recognized by the ubiquitously 
expressed prolactin receptor. Varying degrees of higher 
molecular weight complexes of prolactin are common in 
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human sera and include dimeric prolactin (big prolactin) 
and prolactin•IgG complexes (big-big or macroprolactin) 
[3–6] as well as non-immunoglobulin (IgG)-type macropro-
lactin [7]. The biological activity of these forms, however, is 
minimal, and clinically, most patients with anti-prolactin 
autoantibodies lack the symptoms of hyperprolactinemia [1, 
8, 9]. Thus, macroprolactin is considered clinically irrelevant 
and constitutes a challenging analytical problem in labora-
tory medicine as recently reviewed by the American Associa-
tion of Clinical Endocrinologists and the American College 
of Endocrinology [10]. The significance of this challenge is 
underscored by the fact that the incidence of macroprolatine-
mia range between 4% and 46% among hyperprolactinemic 
patients depending on the referral population [11, 12].
While the most effective method (gold standard) in 
separating macroprolactin from monomeric prolactin is gel 
filtration chromatography (GFC), this method is not compat-
ible with routine screening of a large number of samples. To 
this end, the use of polyethylene glycol (PEG)-mediated pre-
cipitation has been widely adopted as cost and time effective 
alternative approach. Currently, the presence of macroprol-
actin is evaluated by two different screening approaches 
based on either post-PEG recovery level of monomeric prol-
actin [12–14] or the use of post-PEG monomeric prolactin ref-
erence intervals [15, 16]. It is well known that immunoassay 
methods display different reactivity toward macroprolactin 
and that PEG treatment of sera results in co-precipitation 
of up to 20% of the monomeric prolactin present. Thus 
post-PEG recovery levels or post-PEG reference intervals 
(hereinafter called monomeric reference intervals) need to 
be determined for the specific assay method employed and 
using a representative healthy population. As manufactur-
ers of prolactin assays constantly develop and improve their 
products there is a constant need for laboratory (re)evalua-
tion of these tests given the clinical consequences such as 
imaging and pharmacologic or surgical treatment due to 
falsely elevated serum prolactin.
The aim of this study was to evaluate the performance 
of monomeric prolactin reference interval- and monomeric 
prolactin recovery methods for hyper- and macroprolactine-
mia discrimination based on PEG precipitation using a panel 
of contemporary immunoassay methods including one, 
claimed to possess low sensitivity toward macroprolactin.
Materials and methods
Reference subjects and samples
Blood samples for determination of prolactin reference intervals 
were collected between 10:00 and 12:00 AM from healthy female 
(n = 96) and male (n = 128) donors. Only female donors in the fertile 
age and with regular menstruation were included. Participants who 
had night work within 7 days from blood sampling were excluded as 
well as participants (females) who used estrogen-containing contra-
ceptives or were in hormone treatment for menopause. Blood sam-
ples were collected into serum gel tubes (Vacutainer 8.5 mL; BD) and 
left to clot at room temperature for at least 30 min, separated by cen-
trifugation at 200 × g for 10 min within 2–3 h, and stored at 4 °C. The 
following morning each serum samples were divided into aliquots 
and one half stored untreated and one half subjected to PEG precipi-
tation according to the macroprolactin screening protocol described 
below. All samples were stored frozen at − 8 °C until assay-specific 
prolactin measurements were carried out.
Hyperprolactinemic and macroprolactinemic serum samples for 
validation were obtained from routine analysis and stored at – 80 °C.
All participants provided informed consent and the study was 
conducted under the guidance of the Ethics Committee for Region of 
Southern Denmark (S–20162000–76).
Immunoassay methods
Total and post-PEG serum prolactin concentrations were determined 
in 2013/2014 using Architect prolactin 7K76 recalibrated version 
(Abbott), AutoDelfia prolactin; ref. B018–301 (PerkinElmer), Cobas e 
411 prolactin II; ref. 03303093 190 (Roche), Dimension Vista prolactin; 
ref. K6462 (Siemens). Immulite 2000 prolactin; ref. L2KPR ( Siemens), 
Kryptor BRAHMS prolactin; ref. 824.050 (Thermo  Scientific). All 
immunoassays were calibrated against the WHO Third International 
Standard for prolactin (84/500). Prolactin units in mIU/L can be con-
verted to ng/mL or μg/L by dividing by 21.2 for Cobas,  Dimension 
Vista, and Immulite assays; by 21.0 for Architect and  Kryptor assays; 
and by 36 for the AutoDelfia assay.
Interassay CVs for all automated analyzers were determined using 
Seronorm Immunoassay Liq-1/2 (Sero) and ranged from 2.2% to 7.8% 
(QC level 1; 148 mIU/L) and from 2.1% to 3.9% (QC level 2; 586 mIU/L).
Macroprolactin screening protocol
Our standard procedure to determine macroprolactin in patient 
samples is based on post-PEG prolactin (monomer) recovery < 50% 
analyzed using the AutoDelfia assay [17, 18]. Only samples above the 
upper limit of the reference interval are considered for macroprolac-
tin testing. Samples with post-PEG prolactin recovery less than 50% 
are denoted “macroprolactin” and the recovered prolactin concen-
trations are provided to the clinicians. In short, precipitation using 
PEG is carried out by mixing 300 μL serum with an equal volume 
of 25% (wt/vol) PEG 6000 (Merck, product 8.04191.100) for 10  min 
followed by centrifugation for 30  min at 3000  rpm (1810 × g). The 
supernatant is transferred to a new tube and analyzed along with a 
non-precipitated but similarly diluted (deionized water) aliquot of 
the same serum sample.
For macroprolactin classification and validation in this study, 
sera were classified macroprolactinemic if PEG recovery was < 50% 
as determined by the AutoDelfia method and prolactin concentration 
was contained in the reference interval after correction for prolac-
tin monomer content (Table 3 and Supplemental Data, Table S2) as 
determined by GFC/AutoDelfia analysis.
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Gel filtration chromatography
GFC analysis was carried out by equilibrating a Superdex 75 10/300 
GL gel filtration column (GE Healthcare) with PBS (137  mmol/L 
sodium chloride, 2.7  mmol/L KCl, 10  mmol/L sodium phosphate, 
2 mM potassium dihydrogen phosphate, pH 7.4) using an ÄKTA Puri-
fier FPLC system (GE Healthcare). Each serum sample was cleared by 
centrifugation for 5 min at 20.000 × g and 100 μL was injected and 
loaded onto the column and fractionated at a flow rate of 0.5 mL/min. 
A protein elution profile was obtained at a wavelength at 280 nm and 
fractions of 0.5 mL were collected and subjected to analysis for pro-
lactin using the AutoDelfia assay. The molecular weight marker pro-
teins (thyroglobulin, bovine γ-globulin, chicken ovalbumin, equine 
myoglobin, and vitamin B12, MW 1350–670,000) used as gel filtra-
tion standards (Bio-Rad Laboratories) were analyzed in triplicate to 
obtain a calibration curve for molecular weight determinations.
Statistical analysis
Data handling and statistical analysis was carried out using Micro-
soft Excel 2010 and Analyse it for Microsoft Excel 3.90.1 (Microsoft). 
Data outliers were detected using Dixon’s Q-test for outlier detection, 
as implemented in the RefVal program [19].
Results
Baseline characteristics of healthy female 
and male serum prolactin and parametric 
reference intervals for multiple commercial 
immunoassay methods
Female and male total and monomeric serum prolac-
tin concentrations were determined using six differ-
ent commercially available automated immunoassay 
methods. The female data consisted of samples from 96 
individuals (age 19–66  years, mean 43  years) and the 
male data consisted of samples from 128 individuals 
(age 17–66 years, mean 40 years). The exclusion/inclu-
sion criteria used for enrolling participants in this study 
were based on common biological causes affecting pro-
lactin levels as described (Materials and methods). One 
sample was removed from the male panel as an outlier 
according to Dixon’s Q-test. Female and male total and 
monomeric prolactin data appeared nongaussian dis-
tributed according to histograms and Anderson-Darling 
coefficients (1.93–4.78) as well as differences between 
mean and median values (Table  1). By log transforma-
tion, all data approached a normal distribution and 
Anderson-Darling coefficients declined (0.23–0.99). 
The transformed data were hence used to calculate 
parametric 95% reference intervals for each method 
investigated as presented in Table 2 and Supplemental 
Data, Table S1 along with manufacturer provided ref-
erence intervals. The upper 97.5th percentile reference 
limits ranged from 294  mIU/L (Kryptor) to 505  mIU/L 
(Architect) in females and from 291  mIU/L (Kryptor) to 
398  mIU/L (AutoDelfia) in males. Monomeric prolactin 
reference intervals in females and males, respectively, 
ranged from 209 mIU/L (Dimension Vista) to 331 mIU/L 
(Kryptor) and from 194  mIU/L (Dimension Vista) to 
303 mIU/L (Kryptor). The mean post-PEG recovery per-
centage in females and males, respectively, ranged from 
61% (AutoDelfia) to 122% (Kryptor) and from 65% (Archi-
tect) to 120% (Kryptor).
Validation of monomeric prolactin reference 
intervals and comparison of macroprolactin 
screening methods
To evaluate the classification of hyper- and macroprol-
actinemia using monomeric reference intervals, we col-
lected sera from patients with hyperprolactinemia and 
macroprolactinemia (n = 27) according to our existing 
screening regime (Materials and methods). Each sample 
was subjected to GFC separation, and the resulting frac-
tions were analyzed using the AutoDelfia prolactin method. 
The resulting chromatogram of a representative hyperpro-
lactinemic sample (S8) shows a major peak at 12 mL and a 
minor peak at 10 mL of elution volume (Figure 1A). From 
the molecular weight standard curve (Figure 1A, inset) the 
calculated native molecular size of the base peak corre-
sponded to monomer prolactin (23–29 kDa) and the minor 
peak corresponded to dimeric prolactin (53–57 kDa) also 
referred to as big prolactin. For comparison, a macropro-
lactinemic sample (S25) yielded an additional prolactin 
peak at 8 mL which corresponded to macroprolactin (135–
171 kDa) also referred to as big-big prolactin (Figure 1B). 
Using this GFC approach the monomer prolactin percent-
age was calculated for all 27 validation samples and used 
to correct total prolactin concentrations for monomeric 
prolactin content, as determined on each of five immuno-
assay platforms (Table 3). These data were used to obtain a 
robust assignment of the samples as true hyper- or macro-
prolactinemic (Materials and methods and Supplemental 
Data, Table S2). Sera that were reclassified with respect 
to the reference classification ranged from 4% (Cobas) 
to 15% (Architect and Kryptor) when monomeric refer-
ence intervals (Table 2) were applied to the validation set 
(Tables 3 and 4). For comparison to the widely used post-
PEG recovery cutoff method where samples are classified 
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as macroprolactinemic when recovery is below a predeter-
mined recovery cutoff, we calculated the percentage of the 
samples which would change classification at recovery 
cutoffs between 40% and 100% (Table 4). Accordingly, the 
monomeric reference interval method showed elevated 
discordant classification [mean 2.8; 95% confidence inter-
val (CI) 1.2–4.4] compared to the post-PEG recovery cutoff 
method (mean 1.8; 95% CI 0.8–2.8). The two monomer/
macroprolactin discrimination methods did not differ 
significantly (p = 0.089). Among macroprolactinemic sera 
evaluated by both discrimination methods, the Cobas and 
the Architect/Kryptor prolactin assays showed the lowest 
and the highest number of misclassifications, respec-
tively. The post-PEG recovery cutoff method improved 
classification for Architect (40% cutoff), Kryptor (80% 
cutoff) and Immulite (40% and 50% cutoffs) compared to 
the monomeric reference interval method.
Comparison of Kryptor and AutoDelfia assay 
sensitivity to macroprolactinemia 
Among the immunoassay methods tested, only prolactin 
measurements with the Kryptor method is claimed not to 
be interfered by macroprolactin and hence can be used 
without performing PEG precipitation of macroforms.
To explore the difference in macroprolactin sensitiv-
ity between our current AutoDelfia immunoassay and the 
Kryptor method, we performed Passing-Bablok regression 
for total and post-PEG hyperprolactinemic and macro-
prolactinemic samples (Figure  2A). For the hyperpro-
lactinemic samples, we obtained a high level of agreement 
between the methods for both total and post-PEG prolactin 
measurements (Kryptor = − 182 + 0.78 × AutoDelfia, r = 1.00 
and Kryptor = 451 + 0.86 × AutoDelfia, r = 1.00). On the con-
trary, the macroprolactinemic samples showed reduced 
Table 1: Descriptive statistics for total and post-PEG prolactin (mIU/L) in serum samples from healthy male and female donors for the 
 immunoassay platforms indicated.
Method   Minimum  Maximum   Mean   Median   SD   Normalitya   Donor ageb
Total prolactin            
 Males (n = 127)               40 (17–66)
  Architect   56  418  169  150  70  3.03 (0.56) 
  AutoDelfia   51  490  185  168  80  2.25 (0.23) 
  Cobas   56  460  179  156  76  3.21 (0.71) 
  Dimension vista   43  379  146  126  64  3.51 (0.68) 
  Immulite   40  392  146  124  67  3.85 (0.72) 
  Kryptor   48  336  143  127  59  3.36 (0.65) 
 Females (n = 96)               43 (19–66)
  Architect   66  512  201  177  87  3.23 (0.54) 
  AutoDelfia   75  781  231  200  122  4.78 (0.78) 
  Cobas   74  524  208  189  85  2.52 (0.39) 
  Dimension vistac   57  452  173  153  77  2.91 (0.47) 
  Immulite   51  502  169  148  84  4.35 (0.99) 
  Kryptor   54  414  154  141  57  1.93 (0.42) 
Post-PEG (monomeric) prolactin            
 Males (n = 127)               40 (17–66)
  Architect   39  249  108  97  40  2.70 (0.50) 
  AutoDelfia   37  273  117  104  46  2.76 (0.60) 
  Cobas   39  279  117  104  46  2.60 (0.39) 
  Dimension vista   33  228  96  84  39  2.67 (0.44) 
  Immulite   52  269  128  116  45  2.37 (0.49) 
  Kryptor   64  367  165  149  58  2.53 (0.53) 
 Females (n = 96)               43 (19–66)
  Architect   51  292  121  111  43  2.73 (0.51) 
  AutoDelfia   54  323  132  121  50  2.30 (0.38) 
  Cobas   49  316  130  119  49  2.45 (0.43) 
  Dimension vistac   41  271  107  97  42  2.57 (0.42) 
  Immulite   68  354  144  130  51  2.74 (0.63) 
  Kryptor   84  428  182  169  63  2.09 (0.33) 
aNormality was tested using the Anderson-Darling method. Numbers are given as the A2 statistic and numbers in parentheses are 
A2  statistics based on logarithm transformed data. bDonor age is represented as mean and range in parenthesis. cDimension Vista females 
data (n = 95).
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agreement (Kryptor = 321 + 0.06 × AutoDelfia, r = 0.49) in 
the absence of PEG precipitations and improved agree-
ment (Kryptor = − 239 + 3.17 × AutoDelfia, r = 0.71) after 
PEG precipitation. Taken together, these results indicate 
that the two methods possess different sensitivity to 
macro forms of prolactin.
To further investigate this discrepancy, we compared 
the immunoreactivity of the two methods toward the 
different prolactin forms in GFC fractioned serum. The 
Kryptor method exhibited significantly lower reactivity 
against macroprolactin compared with the AutoDelfia 
method using a hyperprolactinemic sample with a signifi-
cant content of macroprolactin (Figure 2B, Table 3, S12). 
When analyzing a macroprolactinemic sample with a pre-
dominant content of macroprolactin (Figure 2C, Table 3, 
S20) likewise less macro reactivity was obtained using the 
Kryptor method but still the vast portion of the total reac-
tivity was achieved for the macro form.
Finally, we addressed the utility of all assay methods 
in classifying macroprolactinemic sera in the absence of 
PEG precipitation. We found that all macro sera (12/12) for 
all assay methods (except for serum S19, Kryptor, Table 3) 
whose initially elevated prolactin levels were, due to mac-
roforms, classified as hyperprolactinemic along with their 
corresponding total prolactin reference intervals obtained 
in this study.
Discussion
In the present study, we have provided gender-specific 
total and monomeric prolactin reference intervals for six 
Table 2: Parametric reference intervals (95%) for total- and post-PEG prolactin (mIU/L) in serum samples from females and males for each 
immunoassay platform indicated.
Method   2.5th Lower 
percentile, mIU/L
  97.5th Upper 
percentile, mIU/L
  Manufacturer 
reported RI, mIU/L
  Mean Post-PEG 
recovery, %
Total prolactin      
 Females (n = 96)
  Architect   84 (75–94)   409 (365–458)  109–557   N/A
  AutoDelfia   85 (75–97)  505 (445–574)  111–590   N/A
  Cobas   89 (79–99)  418 (374–468)  102–496   N/A
  Dimension Vistab   69 (61–78)  363 (322–409)  47–642   N/A
  Immulite   64 (56–72)  367 (323–416)  40–530   N/A
  Kryptor   71 (64–78)  294 (265–326)  80–435a   N/A
 Males (n = 127)
  Architect   71 (64–78)  347 (314–383)  73–407   N/A
  AutoDelfia   72 (65–80)  398 (357–443)  73–474   N/A
  Cobas   73 (66–81)  372 (335–411)  86–324   N/A
  Dimension vista   57 (51–64)  311 (280–346)  53–369   N/A
  Immulite   56 (50–62)  317 (284–353)  53–360   N/A
  Kryptor   59 (54–66)  291 (264–322)  59–254a   N/A
Post-PEG (monomeric) prolactin      
 Females (n = 96)
  Architect   58 (53–64)  224 (203–247)  ND   63 (21–81)
  AutoDelfia   60 (54–67)  254 (229–282)  ND   61 (15–87)
  Cobas   58 (49–70)  257 (222–316)  ND   64 (38–84)
  Dimension Vistab   48 (43–53)  209 (188–233)  ND   64 (26–80)
  Immulite   71 (64–78)  262 (239–288)  ND   91 (34–135)
  Kryptor   90 (82–99)  331 (301–363)  ND   122 (65–261)
 Males (n = 127)
  Architect   50 (45–54)  208 (190–228)  ND   65 (25–81)
  AutoDelfia   51 (46–56)  233 (212–257)   ND   65 (23–91)
  Cobas   51 (46–56)  232 (211–255)  ND   66 (25–80)
  Dimension vista   41 (37–45)  194 (176–214)  ND   67 (25–91)
  Immulite   61 (56–72)  237 (218–258)  ND   88 (34–172)
  Kryptor   80 (73–87)  303 (279–330)  ND   120 (45–218)
ND, not determined. a5th–95th percentile. bFemale reference intervals using healthy donors (n = 95) subjected to exclusion criteria as 
described in Materials and methods (i.e. regular menstrual cycle, no hormonal therapy and no night shift). Numbers in parenthesis are 90% 
confidence intervals. Post-PEG recovery percentage is given as mean value and range in parenthesis.
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commonly used immunoassay platforms in laboratory 
medicine. Except for male reference intervals for Cobas 
and Kryptor, the upper limits determined in this study 
(Table 2) were lower (range 12%–43%) than that reported 
by the manufacturers. This trend was also reported in 
an earlier study of multiple prolactin methods, despite 
the male reference intervals were derived from a smaller 
sample size [15]. In this study we excluded female donors 
due to confounding such as irregular menstruations, use 
of estrogen containing contraceptives or hormone treat-
ment for menopause. Likewise donors who had recently 
been working at night were excluded (Materials and 
methods). Total serum prolactin is higher in females than 
males; accordingly, the female reference interval provided 
in this study was on average 15% higher than the male ref-
erence interval for all methods. Previously published ref-
erence intervals for three of the six methods studied here 
showed a 45% difference between females and males [15] 
and the manufacturer intervals showed a mean difference 
of 46%. None of the studies provided any details regard-
ing exclusion criteria for the female participants, indicat-
ing that those reference intervals are applicable to a wider 
range of females.
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Figure 1: Analysis of prolactin monomer and macro species in serum.
Serum (0.1 mL) was subjected to GFC and prolactin immunoreactiv-
ity was analyzed in the resulting fractions using the AutoDelfia 
method. The interpolated molecular weight (kDa) range of each 
peak fraction is indicated. (A) Serum from a patient (S8, Table 3) 
with hyperprolactineamia. Inset: GFC standard proteins; Kav plotted 
against molecular weight (kDa). (B) Serum from a patient with 
macroprolactinemia (S25; Table 3) causing discordant classification 
using post-PEG reference intervals. Prl monomer 23–29 kDa, Prl Big 
53–67 kDa, Prl Big-Big 135–171 kDa.
All monomeric upper reference limits were markedly 
lower than that obtained for total serum prolactin except 
for Kryptor which was also reflected in the mean post-
PEG recovery which ranged from 65% for Architect and 
AutoDelfia to 120% for Kryptor. These recoveries reflect 
not only protein precipitation by PEG (i.e. macroprolac-
tin, big prolactin, and some degree of monomeric prolac-
tin) but also positive or negative PEG interference of the 
immunoassay per se. While common practice for macro-
prolactin screening among hyperprolactinemic sera has 
been reporting the presence of macropro lactin when post-
PEG recovery was below a certain cutoff ( typically below 
40% or 50%) depending on the method used [20], some 
researchers have advocated for the use of post-PEG mono-
meric reference intervals [16]. To this end, we evaluated 
the ability of both approaches to correctly classify hyper-
prolactinemic and macroprolactinemic sera as determined 
using GFC analysis (Figure 1 and Tables 3 and 4). We found 
that while the monomeric reference interval approach had 
a marginally higher rate of discordant classification for the 
Architect, Immulite, and Kryptor methods, the AutoDelfia 
and Cobas methods reclassified equally at low levels for 
both approaches. Notably, the optimal recovery cutoff for 
three methods was 40%, whereas the optimal recovery 
cutoff for Immulite and Kryptor was found to be 50% and 
80%, respectively. The latter result was expected due to a 
higher mean post-PEG recovery found for female and male 
sera using these methods as previously discussed.
From a clinician’s point of view, laboratory reporting 
of a monomeric (post-PEG) prolactin concentration along 
with a monomeric reference interval may be more useful 
and easier to interpret than the reporting of macroprolac-
tin along with a recovered prolactin concentration. Never-
theless, the recovery approach is more easily transferable 
to laboratories which are not establishing local reference 
intervals and where the population composition differ sig-
nificantly from that of which published reference intervals 
where derived.
Clearly, macroprolactin screening of hyperprolactine-
mic sera requires more laborious preanalytical handling 
in the laboratory and thus, methods that are absolutely 
insensitive to macroprolactin should be preferred. Intrigu-
ingly, one of the assays (Kryptor) has been claimed not to 
detect macroprolactin and hence be used without any PEG 
precipitation step. Using the validation sera, the macro-
prolactinemic samples expectedly showed poor agree-
ment in the absence of PEG precipitations and improved 
agreement after PEG precipitation (removing macro-
forms), indicating that the two methods possess different 
sensitivity to macroforms of prolactin. By evaluating two 
of the macroprolactinemic samples by GFC analysis, this 
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difference in macroprolactin sensitivity was confirmed 
by higher reactivity toward monomeric prolactin by the 
Kryptor method (Figure 2B and C). However, the method 
also showed some reactivity toward macroprolactin and 
failed to classify the macroprolactinemic sera correctly 
in the absence of PEG precipitation. Thus, our data sup-
ports the continued use of PEG precipitation of hyperpro-
lactinemic sera for macroprolactin screening for all of the 
methods tested in this study.
The incidence of macroprolatinemia in our hospi-
tal laboratory setting was estimated to be 10% (n = 924), 
using a PEG recovery cutoff of 50%. This number may be 
positively biased because our laboratory receives patient 
samples from other sites for macroprolactin screening. 
Other studies have reported very different macropro-
latinemia incidences ranging from 4% to 46% [11, 12]. 
Despite these differences, interference from macroprol-
actin remains a clinically important challenge for labora-
tory specialist and endocrinologist and thus, requires the 
implementation of a validated screening strategy. Accord-
ing to clinical guidelines for the diagnosis and treatment 
of hyperprolactinemia, pituitary magnetic resonance 
imaging is recommended to establish the diagnosis and to 
evaluate the treatment [21]. Thus, patients with macropro-
lactinemia may be subjected to unnecessary and expen-
sive diagnostic procedures.
The accuracy of the reference intervals provided in 
this study was limited by the sample size, especially for the 
female donors. Also, it is likely that the use of exclusion 
criteria for selecting healthy donors contributed to lower 
reference intervals and thus being less representative of 
a general population. In our hospital setting, we recom-
mend the application of those criteria to avoid confound-
ing due to biological cyclic variation. Validation of the 
monomeric reference intervals was limited by the number 
of sera selected due to the relatively high number of down-
stream analyses required for cross-validation on the five 
platforms including GFC/AutoDelfia. Unfortunately, lack 
of sufficient validation sample material prevented the 
evaluation of the Dimension Vista method in relation to 
macroprolactin screening. Another limitation of this study 
was the assignment of macroprolactinemia among the 
sera used for validation. We used sera whose concentra-
tions initially were above the upper reference limit. Then 
total prolactin concentrations were corrected for actual 
monomeric prolactin content (as determined by GFC) to 
become normo-prolactinemic according to the total pro-
lactin reference interval. This strategy could potentially 
lead to an overestimation of the number of samples clas-
sified as macroprolatinemic in our study because the 
use of a true monomeric reference interval based on GFC 
analysis of each sample expectedly would be lower due 
to the discrimination between prolactin isoforms. The use 
of a monomer-corrected reference interval according to a 
previous reported upper range of monomeric prolactin of 
85% for 21 normal sera [15] did not change classification 
for any specimen (Supplemental Data, Table S2). Finally, 
we cannot exclude biased macroprolactin assignment due 
to flawed AutoDelfia assay recognition of macroforms in 
the GFC fractions. However, the degree of recovery corre-
lated with the content of macroforms detected using GFC/
AutoDelfia analysis (Table 3). Based on the monomeric 
reference intervals determined in this study, discordant 
classification ranged 4%–15% for all sera (Tables 3 and 4) 
and overall agreement of classification was 90%. Taken 
together, the specificity of the monomeric reference inter-
val method is moderate to high but for sera with post-PEG 
prolactin concentrations being close to the upper limit, 
the post-PEG recovery percentage could additionally be 
used for estimating the magnitude of macroprolactin 
present in the patient sample.
Current macroprolactinemia screening methods, 
based on PEG precipitation, perform similarly regarding 
macroprolactin detection. For clinical use, however, the 
Table 4: Discordant classification of hyper- and macroprolactinemia as determined using the post-PEG reference interval and post-PEG 
recovery methods.
Immunoassay platform Architect AutoDelfia Cobas Immulite Kryptor
n (%)
Post-PEG RI method 4 (15) 2 (7) 1 (4) 3 (11) 4 (15)
Post-PEG recovery method
 Recovery cutoff, %
  40 2 (7) 2 (7) 1 (4) 3 (11) 12 (44)
  50 4 (15) 4 (15) 1 (4) 1 (4) 9 (33)
  60 4 (15) 4 (15) 2 (7) 3 (11) 8 (30)
  80 7 (26) 10 (37) 7 (26) 4 (15) 3 (11)
  100 16 (59) 15 (56) 13 (48) 10 (37) 9 (33)
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Figure 2: Assessment of macroprolactin sensitivity for Kryptor and 
AutoDelfia immunoassay methods.
(A) Passing-Bablok regression of prolactin analyzed using the 
methods indicated on total hyperprolactinemic sera (blue circles; 
r = 1.00), post-PEG hyperprolactinemic sera (light blue circles; 
r = 1.00), total macroprolactinemic sera (red squares; r = 0.46),  
post-PEG macroprolactinemic sera (orange squares; r = 0.64), 
(B) Prolactin immunoreactivity in GFC fractionated sera ( AutoDelfia: 
grey squares; Kryptor: filled circles) using hyperprolactinemic 
serum, H12, Table 3 (B). Macroprolactinemic serum, S20; Table 3 (C).
monomeric reference interval method is simpler by pro-
viding an easy interpretable monomeric prolactin concen-
tration along with a monomeric reference interval. Among 
the prolactin assays studied, no assay could accurately 
classify hyperprolactinemia in the presence of macroprol-
actin without use of PEG precipitation.
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